Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia

Otolaryngology - Head and Neck Surgery

Volumn 136, Issue 6, 2007, Pages 894-899

  Chang, Christopher Y ^a   Chabot, Peter ^b   Thomas, James P ^c  

^a Fauquier Ear Nose and Throat Consultants PLC ^*  (United States)

^b Minimax Consulting LLC   (United States)

^c MD LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADDUCTION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DYSPHONIA; ELECTROMYOGRAM; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOICE CHANGE;

BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NEUROMUSCULAR AGENTS; SOUND SPECTROGRAPHY; TREATMENT OUTCOME; VOICE DISORDERS; VOICE QUALITY;

EID: 34249818781     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2007.01.035     Document Type: Article

References (19)

1. Sulica L. Contemporary management of spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg 12 (2004) 543-548
2. Koufman J., Rees C., Halum S., et al. Treatment of adductor-type spasmodic dysphonia by surgical myectomy: a preliminary report. Ann Otol Rhinol Laryngol 115 (2006) 97-102
3. Chhetri D., Mendelsohn A., Blumin J., et al. Long-term follow-up results of selective laryngeal adductor denervation-reinnervation surgery for adductor spasmodic dysphonia. Laryngoscope 116 (2006) 635-642
4. Isshiki N., Haji T., Yamamoto Y., et al. Thyroplasty for adductor spasmodic dysphonia: further experiences. Laryngoscope 111 (2001) 615-621
5. Blitzer A., Brin M., and Stewart C. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108 (1998) 1435-1441
6. Esquenazi A. Botulinum neurotoxin in muscle overactivity. J Head Trauma Rehabil 20 (2005) 563-567
7. Blitzer A., and Brin M. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 100 (1991) 85-89
8. Baker R., Jasinski M., Maciag-Tymecka I., et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Develop Med Child Neurol 44 10 (2002) 666-675
9. Satila H., Kotamaki A., Koivikko M., et al. Low- and high-dose botulinum toxin a treatment: a retrospective analysis. Pediatr Neurol 34 (2006) 285-290
10. Flynn T., Carruthers J., Carruthers J., et al. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study. Dermatol Surg 29 (2003) 943-951
11. Welchel D., Brehmer T., Brooks P., et al. Molecular targets of botulinum toxin at the mammalian neuromuscular junction. Move Disord 19 (2004) S7-S16
12. Shaari C., George E., Wu B., et al. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 101 (1991) 960-964
13. George E., Zimbler M., Wu B., et al. Quantitative mapping of the effect of botulinum toxin injections in the thyroarytenoid muscle. Ann Otol Rhinol Laryngol 101 (1992) 888-892
14. Hsu T., Dover J., and Arndt K. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 140 (2004) 1351-1354
15. Wyndaele J., and Van Dromme S. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 40 (2002) 599-600
16. Grumelli C., Verderio C., Pozzi D., et al. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicol 26 (2005) 761-767
17. Shaari C., and Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 16 (1993) 964-969
18. Hamjian J., and Walker F. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve 17 (1994) 1385-1392
19. Bastian R, Thomas J. Survey of patients who discontinued botulinum toxin A injections for spasmodic dysphonia. In Western Section Triologic Society, San Francisco, CA; 1/8/2000.